Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Healthcare Medical Devices

Therma Bright Inc. is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. The Venowave is a medical compression pump that is lightweight, compact, battery operated, designed to treat and alleviate the symptoms associated with poor circulation.

TSXV:THRM - Post by User

Therma Bright Inc > Min valuation for Therma once product available at least 10x

<< Previous

Bullboard Posts

Next >>

Post by magnuswaveon Nov 10, 2020 11:27am

221 Views

Post# 31870245

Min valuation for Therma once product available at least 10x

Comparing Medmira which has basically no sales of any relevance carries a market cap of $154 mln based on a current price of 25 cents. The market is willing to give Mir this market cap based on potential. If we apply the same market cap to thrm once product available we should expect at least 70 to 80 cents. This is how we should be looking at THRM as a spec paly rather than picking baseless numbers. The collective market particpants will re- rate once a product available which may only be a few weeks away. Below are the latest #'s and they are not anything to get excited about so the question should be is MIR overpriced or THRM underpriced. Split the differnece and you still should get 40 to 50 cents for THRM.

MedMira Reports Third Quarter Results FY2020

June 29, 2020 20:00 ET | Source: MedMira Inc.

HALIFAX, Nova Scotia, June 29, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2020.

Important Notice

The Company’s Q3 FY2020 statements have recorded all financial transactions from the 1^st of February 2020 until the 30^th of April 2020. Any subsequent transactions after the end of the third quarter are not recorded in the Company’s financial statement and balance sheet for Q3 FY2020.

Profit and Loss Highlights

Revenue: The Company recorded revenues in Q3 FY2020 of $87,207 compared to $143,387 in Q3 FY2019. The decrease of these revenues was due to the delay of orders received due to the COVID-19 worldwide situation.
Gross Profit: The Company recorded a gross profit in Q3 FY2020 of $70,344 compared to $119,980 for the same period last year. The overall gross margin percentage on sales was 81% compared to a gross margin of 84% in the same quarter last financial year.
Operating expenses: The Company recorded for this quarter operating expenses of $602,996 compared to $429,205 in Q3 FY2019. The increase of 40% in operating expenses was primarily due to the volatile exchange rates for USD/CAD$ and CHF/CAD$ in the month of March 2020.
Net loss: The Company recorded a net loss of $692,479 compared to $512,558 in Q3 FY2019. The increase is mainly due to the additional costs for the product development of REVEALCOVID-19 Total Antibody Test and the overall world wide economical situation created by COVID-19.